<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2014-4-94-100</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group></article-categories><title-group><article-title>Нидлинг тонкостенной кистозной фильтрационной подушки в раннем периоде после фистулизирующей операции с развитием токсической кератопатии</article-title><trans-title-group xml:lang="en"><trans-title>Early cystic bleb needling revision after glaucoma filtering surgery with toxic keratopathy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>S. Yu.</given-names></name></name-alternatives><email xlink:type="simple">post@glaucomajournal.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каспарова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kasparova</surname><given-names>E. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антонов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Antonov</surname><given-names>A. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Митичкина</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mitichkina</surname><given-names>T. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вострухин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vostrukhin</surname><given-names>S. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафонова</surname><given-names>Д. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Safonova</surname><given-names>D. M.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НИИ глазных болезней» РАМН , Россолимо, д.11A,Б, 119021, Москва, Российская Федерация</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Eye Diseases of Russian Academy of Medical Sciences, 11A,B, Rossolimo St.,119021 Moscow, Russian &#13;
federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «НИИ глазных болезней» РАМН , Россолимо, д.11A,Б, 119021, Москва, Российская Федерация</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Eye Diseases of Russian Academy of Medical Sciences, 11A,B, Rossolimo St.,119021 Moscow, Russian&#13;
federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>14</day><month>01</month><year>2015</year></pub-date><volume>11</volume><issue>4</issue><fpage>94</fpage><lpage>100</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Петров С.Ю., Каспарова Е.А., Антонов А.А., Митичкина Т.С., Вострухин С.В., Сафонова Д.М., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Петров С.Ю., Каспарова Е.А., Антонов А.А., Митичкина Т.С., Вострухин С.В., Сафонова Д.М.</copyright-holder><copyright-holder xml:lang="en">Petrov S.Y., Kasparova E.A., Antonov A.A., Mitichkina T.S., Vostrukhin S.V., Safonova D.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/212">https://www.ophthalmojournal.com/opht/article/view/212</self-uri><abstract><p>В статье описан клинический случай нидлинга высокой тонкостенной отграниченной фильтрационной подушки в раннем периоде после синусотрабекулэктомии с развитием отечной кератопатии. По данным оптической когерентной томографии, высота подушки в наивысшей точке составила 2700 мкм, толщина стенки — 70 мкм. В день обращения пациентке амбулаторно был выполнен нидлинг со вскрытием латеральной стенки подушки и субконъюнктивальным введением раствора дексаметазона, фторурацила и ранибизумаба в соседнюю с подушкой область. В результате процедуры спустя 1,5 часа высота подушки в наивысшей точке уменьшилась в 5 раз, составив 550 мкм, а толщина ее стенки увеличилась до 100 мкм. Больной была рекомендована местная инстилляционная терапия антибактериальным, стероидным и нестероидным противовоспалительными препаратами. На следующий день офтальмотонус снизился с 11 до 4,5 мм рт. ст., что сопровождалось развитием плоской отслойки сосудистой оболочки, купированной с помощью инстилляционной и инъекционной циклоплегической терапии в течение 3 суток. На 6 сутки на фоне умеренного повышения офтальмотонуса у пациентки отмечено появление отека всех слоев роговицы со складками десцеметовой мембраны в центральной и парацентральной зонах. Присоединение метаболической терапии позволило нормализовать состояние роговицы в течение 3 суток, а повторный нидлинг — снизить офтальмонотонус до 6,2 мм рт. ст., что привело к появлению преходящих складок десцеметовой оболочки. Данный клинический случай продемонстрировал методику нидлинга фильтрационной подушки с деструкцией ее стенки в комплексе с применением противовоспалительных, цитостатических и анти-VEGF препаратов для продления гипотензивного эффекта фистулизирующейантиглаукомной хирургии в условиях избыточного рубцевания с развитием токсической декомпенсации эндотелия роговицы, повлекшей за собой отек роговицы со складчатостью десцеметовой мембраны, купированные активной метаболической терапией.</p></abstract><trans-abstract xml:lang="en"><p>Clinical case of high thin-wall cystic limited filtering bleb needling revision in the early post-op period after trabeculectomy with sinusotomy accompanied by toxic keratopathy is presented. Optical coherence tomography (OCT) demonstrated that filtering bleb height was 2700 μm and bleb wall thickness was 70 μm. Bleb needling revision with its lateralwall dissection and subconjunctival injection of dexamethasone, fluorouracil, and ranibizumab near to the bleb site was performed. In 1.5 hours after the procedure, bleb height decreased to 550 μm (by 5 times) while bleb wall thickness increased up to 100 μm. Topical antibacterial, steroid, and non-steroid anti-inflammatory therapy was recommended. The next day IOP level reduced from 11 mm Hg to 4.5 mm Hg. It was accompanied by choroidal effusion that was managed conservatively with cycloplegic agents (drops and injections) for 3 days. On day 6, central corneal edema affecting all layers, Descemet’s membrane folds, and ocular hypertension were revealed. Metabolic therapy resolved corneal edema within 3 days. Re-needling bleb revision decreased IOP level to 6.2 mm Hg. This resulted in transient Descemet’s membrane folds. This paper describes filtering bleb needling revision with its lateral wall dissection and anti-inflammatory, cytostatic, and anti-VEGF agents use to prolong glaucoma filtering surgery effect in excessive scarring. The procedure was accompanied by toxic corneal endothelium decompensation with corneal edema and Descemet’s membrane folds treated with active metabolic therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>трабекулэктомия</kwd><kwd>фильтрационная подушка</kwd><kwd>дексаметазон</kwd><kwd>фторурацил</kwd><kwd>ингибитор VEGF</kwd><kwd>нидлинг</kwd></kwd-group><kwd-group xml:lang="en"><kwd>trabeculectomy</kwd><kwd>filtering bleb</kwd><kwd>dexamethasone</kwd><kwd>fluorouracil</kwd><kwd>anti-VEGF agents</kwd><kwd>needling revision.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Petrov S. Yu. Bleb classification. National Journal glaucoma. 2014; 13 (3): 85‑98. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Petrov S. Yu. Bleb classification. National Journal glaucoma. 2014; 13 (3): 85‑98. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wells A. P., Crowston J. G., Marks J., Kirwan J. F., Smith G., Clarke J. C., et al A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma 2004; 13 (6): 454‑460.</mixed-citation><mixed-citation xml:lang="en">Wells A. P., Crowston J. G., Marks J., Kirwan J. F., Smith G., Clarke J. C., et al A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma 2004; 13 (6): 454‑460.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shmyreva V. F., Petrov S. Yu., Antonov A. A., Pimenidi M. K. Controlled cytostatic therapy in the early postoperative period after glaucoma surgery (preliminary report). Herald of ophthalmology. 2007; 1: 12‑14. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Shmyreva V. F., Petrov S. Yu., Antonov A. A., Pimenidi M. K. Controlled cytostatic therapy in the early postoperative period after glaucoma surgery (preliminary report). Herald of ophthalmology. 2007; 1: 12‑14. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Shmyreva V. F., Petrov S. Yu., Makarova A. S. Causes of long-term decrease of glaucoma surgery hypotensive effect and possibilities of its enhancement. Glaucoma. 2010. 2: 43‑49. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Shmyreva V. F., Petrov S. Yu., Makarova A. S. Causes of long-term decrease of glaucoma surgery hypotensive effect and possibilities of its enhancement. Glaucoma. 2010. 2: 43‑49. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">How A., Chua J. L., Charlton A., Su R., Lim M., Kumar R. S., Crowston J. G., Wong T. T. Combined treatment with bevacizumab and 5‑fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 2010; 51 (2): 928‑932.</mixed-citation><mixed-citation xml:lang="en">How A., Chua J. L., Charlton A., Su R., Lim M., Kumar R. S., Crowston J. G., Wong T. T. Combined treatment with bevacizumab and 5‑fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 2010; 51 (2): 928‑932.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Camejo L., Noecker R. J. Bleb Needling. Glaucoma Today 2007; 1: 57‑60.</mixed-citation><mixed-citation xml:lang="en">Camejo L., Noecker R. J. Bleb Needling. Glaucoma Today 2007; 1: 57‑60.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sengupta S., Venkatesh R., Ravindran R. D. Safety and Efficacy of Using Off-label Bevacizumab Versus Mitomycin C to Prevent Bleb Failure in a Single-site Phacotrabeculectomy by a Randomized Controlled Clinical Trial. J. Glaucoma. 2012; 21 (7): 450‑459.</mixed-citation><mixed-citation xml:lang="en">Sengupta S., Venkatesh R., Ravindran R. D. Safety and Efficacy of Using Off-label Bevacizumab Versus Mitomycin C to Prevent Bleb Failure in a Single-site Phacotrabeculectomy by a Randomized Controlled Clinical Trial. J. Glaucoma. 2012; 21 (7): 450‑459.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Klettner A., Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008; 49 (10): 4523‑4527.</mixed-citation><mixed-citation xml:lang="en">Klettner A., Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008; 49 (10): 4523‑4527.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Horsley M. B., Kahook M. Y. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010; 21 (2): 112‑117.</mixed-citation><mixed-citation xml:lang="en">Horsley M. B., Kahook M. Y. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010; 21 (2): 112‑117.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kahook M. Y. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol. 2010; 150 (3): 399‑403.</mixed-citation><mixed-citation xml:lang="en">Kahook M. Y. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol. 2010; 150 (3): 399‑403.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Petrov S. Yu., Novikov I. A., Dugina A. E. Methods for assessing the functional state of the filtering bleb after glaucoma surgery. RU patent 2423069. 19.11.2009. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Petrov S. Yu., Novikov I. A., Dugina A. E. Methods for assessing the functional state of the filtering bleb after glaucoma surgery. RU patent 2423069. 19.11.2009. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Freiberg F. J., Matlach J., Grehn F., Karl S., Klink T. Postoperative subconjunctival bevacizumab injection as an adjunct to 5‑fluorouracil in the management of scarring after trabeculectomy. Clin Ophthalmol. 2013; 7: 1211‑1217.</mixed-citation><mixed-citation xml:lang="en">Freiberg F. J., Matlach J., Grehn F., Karl S., Klink T. Postoperative subconjunctival bevacizumab injection as an adjunct to 5‑fluorouracil in the management of scarring after trabeculectomy. Clin Ophthalmol. 2013; 7: 1211‑1217.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Walters T., Raizman M., Ernest P., Gayton J., Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007; 33 (9): 1539‑1545.</mixed-citation><mixed-citation xml:lang="en">Walters T., Raizman M., Ernest P., Gayton J., Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007; 33 (9): 1539‑1545.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Brkovic A., Sirois M. G. Vascular +permeability induced by VEGF family members in vivo: Role of endogenous PAF and NO synthesis. J Cell Biochem. 2007; 100 (3): 727‑737.</mixed-citation><mixed-citation xml:lang="en">Brkovic A., Sirois M. G. Vascular +permeability induced by VEGF family members in vivo: Role of endogenous PAF and NO synthesis. J Cell Biochem. 2007; 100 (3): 727‑737.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999; 77: 527‑543.</mixed-citation><mixed-citation xml:lang="en">Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999; 77: 527‑543.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gavard J., Gutkind J. S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006; 8: 1223‑1234.</mixed-citation><mixed-citation xml:lang="en">Gavard J., Gutkind J. S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006; 8: 1223‑1234.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Avetisov S. E., Budzinskaya M. V., Kazaryan E. E., Gyrova I. V. Diagnostic value of lifetime retinal morphometry in patients with subretinal neovascularization. Herald of ophthalmology. 2007; 1: 3‑7. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Avetisov S. E., Budzinskaya M. V., Kazaryan E. E., Gyrova I. V. Diagnostic value of lifetime retinal morphometry in patients with subretinal neovascularization. Herald of ophthalmology. 2007; 1: 3‑7. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Budzinskaya M. V., Pogoda T. V., Strelkova I. D., Chikun E. A., Schegoleva I. V., Kazaryan E. E., Galoyan N. S. The impact of genetic mutations on the subretinal neovascularization clinical picture. Report № 2. The role of HTRA и VEGF genetic polymorphism. Herald of ophthalmology. 2011; 4: 9‑16. (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Budzinskaya M. V., Pogoda T. V., Strelkova I. D., Chikun E. A., Schegoleva I. V., Kazaryan E. E., Galoyan N. S. The impact of genetic mutations on the subretinal neovascularization clinical picture. Report № 2. The role of HTRA и VEGF genetic polymorphism. Herald of ophthalmology. 2011; 4: 9‑16. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Karp J. E., Broder S. Molecular foundations of cancer: new targets for intervention. Nat. Med. 1995; 4 (1): 309‑320.</mixed-citation><mixed-citation xml:lang="en">Karp J. E., Broder S. Molecular foundations of cancer: new targets for intervention. Nat. Med. 1995; 4 (1): 309‑320.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bochmann F., Kaufmann C., Becht C. N., Guber I., Kaiser M., Bachmann L. M., Thiel M. A. ISRCTN12125882 — Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma — Study Protocol. BMC Ophthalmol. 2011; 11: 1.</mixed-citation><mixed-citation xml:lang="en">Bochmann F., Kaufmann C., Becht C. N., Guber I., Kaiser M., Bachmann L. M., Thiel M. A. ISRCTN12125882 — Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma — Study Protocol. BMC Ophthalmol. 2011; 11: 1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Singh R. P., Goldberg I., Mohsin M. The efficacy and safety of itraoperative and / or postoperative 5‑fluorouracil in trabeculectomy and phacotrabeculectomy. Clin. Experiment. Ophtalmol. 2001; 29 (5): 296‑302.</mixed-citation><mixed-citation xml:lang="en">Singh R. P., Goldberg I., Mohsin M. The efficacy and safety of itraoperative and / or postoperative 5‑fluorouracil in trabeculectomy and phacotrabeculectomy. Clin. Experiment. Ophtalmol. 2001; 29 (5): 296‑302.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Knapp A., Heuer D. K., Stern G. A., Driebe W. T. Jr. Serious corneal complications of glaucoma filtering surgery with postoperative 5‑fluorouracil. Am J Ophthalmol. 1987; 103 (2): 183‑187.</mixed-citation><mixed-citation xml:lang="en">Knapp A., Heuer D. K., Stern G. A., Driebe W. T. Jr. Serious corneal complications of glaucoma filtering surgery with postoperative 5‑fluorouracil. Am J Ophthalmol. 1987; 103 (2): 183‑187.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas R., Jacob A., Raju R., Gieser S. C., Sen S. Incidence of complications following 5‑fluorouracil with trabeculectomies. Indian J Ophthalmol. 1993; 41 (4): 185‑186.</mixed-citation><mixed-citation xml:lang="en">Thomas R., Jacob A., Raju R., Gieser S. C., Sen S. Incidence of complications following 5‑fluorouracil with trabeculectomies. Indian J Ophthalmol. 1993; 41 (4): 185‑186.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Heur D. K., Parrish R. K., Gressel M. G., et al. 5‑Fluorouracil and glaucoma filtering surgery. II: A pilot study. Ophthalmology 1984; 91: 384‑394.</mixed-citation><mixed-citation xml:lang="en">Heur D. K., Parrish R. K., Gressel M. G., et al. 5‑Fluorouracil and glaucoma filtering surgery. II: A pilot study. Ophthalmology 1984; 91: 384‑394.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Heur D. K., Parrish R. K., Gressel M. G., et al. 5‑Fluorouracil and glaucoma filtering surgery: intermediate follow-up of a pilot study. Ophthalmology 1986; 93:1537‑1546.</mixed-citation><mixed-citation xml:lang="en">Heur D. K., Parrish R. K., Gressel M. G., et al. 5‑Fluorouracil and glaucoma filtering surgery: intermediate follow-up of a pilot study. Ophthalmology 1986; 93:1537‑1546.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Weinreb R. N. Adjusting the dose of 5‑Fluorouracil after filtration surgery to minimize side effects. Ophthalmology 1987; 94: 564‑570.</mixed-citation><mixed-citation xml:lang="en">Weinreb R. N. Adjusting the dose of 5‑Fluorouracil after filtration surgery to minimize side effects. Ophthalmology 1987; 94: 564‑570.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
